MEDI-551, an afucosylated anti-CD19 antibody that acts predominantly via ADCC and demonstrated a 30 % response rate in CLL as a monotherapy, is under investigation in combination with bendamustine in a phase II setting in patients with relapsed/refractory (RR) CLL (NCT01466153). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.